Copyright: ©Author(s) 2026.
World J Gastrointest Surg. Apr 27, 2026; 18(4): 116371
Published online Apr 27, 2026. doi: 10.4240/wjgs.v18.i4.116371
Published online Apr 27, 2026. doi: 10.4240/wjgs.v18.i4.116371
Table 2 Comparative analysis of surgical indicators, health economics indicators, efficacy evaluation indicators, and postoperative medical management
| EFR group (n = 98) | STER group (n = 99) | LMIS group (n = 345) | H/χ2 value | P value | |
| Surgical indicators | |||||
| Operative times [M (Q1, Q3), minutes] | 44.5 (27.0, 78.0) | 59.5 (33.0, 91.0) | 87.0 (60.0, 115.0) | 73.33 | < 0.001 |
| Blood loss [M (Q1, Q3), mL] | 5.0 (3.0, 8.0) | 3.0 (2.0, 5.0) | 20.0 (10.0, 50.0) | 251.67 | < 0.001 |
| Health economics indicators | |||||
| Hospital stay [M (Q1, Q3), days] | 8.0 (7.0, 9.0) | 8.0 (7.0, 9.0) | 9.0 (7.0, 11.0) | 6.53 | 0.038 |
| Surgical costs [M (Q1, Q3), CNY] | 16753.4 (12914.0, 24603.0) | 13963.0 (9477.1, 16944.6) | 25127.8 (19532.8, 32571.5) | 139.62 | < 0.001 |
| Surgical costs [M (Q1, Q3), USD] | 2435.1 (1877.0, 3576.0) | 2029.5 (1377.4, 2462.9) | 3652.2 (2839.1, 4734.2) | 139.62 | < 0.001 |
| Efficacy evaluation indicators | |||||
| Overall postoperative adverse event incidence, n (%) | 34 (34.7) | 49 (49.5) | 2 (0.6) | 171.89 | < 0.001 |
| Postoperative abdominal pain incidence, n (%) | 13 (13.3) | 26 (26.3) | 1 (0.3) | 81.98 | < 0.001 |
| Postoperative fever incidence, n (%) | 28 (28.6) | 42 (42.4) | 0 (0.0) | 149.17 | < 0.001 |
| Postoperative hematemesis or melena incidence, n (%) | 2 (2.0) | 2 (2.0) | 0 (0.0) | 8.15 | 0.017 |
| Postoperative medical management | |||||
| Duration of nasogastric tube placement [M (Q1, Q3), days] | 0.0 (0.0, 4.0) | 0.0 (0.0, 0.0) | 1.0 (1.0, 3.0) | 89.92 | < 0.001 |
| Method of PPI administration, n (%) | 117.26 | < 0.001 | |||
| No | 1 (1.0) | 0 (0.0) | 10 (2.9) | ||
| Intravenous drip | 66 (67.3) | 81 (81.8) | 335 (97.1) | ||
| Intravenous pumping | 31 (31.6) | 18 (18.2) | 0 (0) | ||
| PPI use duration [M (Q1, Q3), days] | 6.0 (5.0, 7.0) | 6.0 (5.0, 7.0) | 4.0 (3.0, 5.0) | 148.95 | < 0.001 |
| Types of anti-infective agents, n (%) | 374.83 | < 0.001 | |||
| No | 1 (1.0) | 0 (0.0) | 3 (0.9) | ||
| Monotherapy with a first-line or second-line antimicrobial | 33 (33.7) | 18 (18.2) | 332 (96.2) | ||
| Combination therapy with metronidazole for anaerobic coverage | 47 (48.0) | 71 (71.7) | 0 (0.0) | ||
| Escalation to higher-level antimicrobials | 17 (17.3) | 10 (10.1) | 10 (2.9) | ||
| Duration of antimicrobial treatment [M (Q1, Q3), days] | 5.0 (4.0, 6.0) | 5.0 (4.0, 6.0) | 4.0 (3.0, 5.0) | 68.45 | < 0.001 |
| Time to resume oral intake [M (Q1, Q3), days] | 6.0 (5.0, 7.0) | 5.0 (4.0, 6.0) | 2.0 (1.0, 3.0) | 283.10 | < 0.001 |
- Citation: Wang LH, Wu X, Sun YT, Liu PF, Wang JF, Yuan YQ, Li HK, Linghu EQ, Chen QQ. Endoscopic super-minimally invasive vs laparoscopic wedge resection for muscularis-propria-originating extraluminal gastric tumors: Efficacy and selection. World J Gastrointest Surg 2026; 18(4): 116371
- URL: https://www.wjgnet.com/1948-9366/full/v18/i4/116371.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v18.i4.116371